What Companies Make GLP 1 Drugs

Introduction

Finding the right path for weight management often feels like a cycle of trial and error. You may have spent years navigating restrictive diets or intensive exercise programs only to find the results don’t last. Recently, the conversation around weight loss has shifted toward metabolic health and a class of medications known as GLP-1 receptor agonists. These treatments, which mimic a hormone naturally found in your body, have changed how we approach chronic weight management.

At TrimRx, we believe that understanding the science and the industry behind these medications is the first step toward a more empowered health journey. If you are wondering whether a personalized prescription program could be a fit, you can take the free assessment quiz to get started. This article will look at the major pharmaceutical companies currently leading the market, the emerging players developing the next generation of treatments, and how personalized programs can help you navigate these options safely. By the end of this guide, you will have a clear picture of the companies shaping the future of metabolic health.

The Pioneers of GLP-1 Technology

The development of GLP-1 medications was not an overnight success. It is the result of decades of research into how the body processes sugar and signals hunger. GLP-1 stands for glucagon-like peptide-1, which is a hormone produced in the gut that tells your brain you are full and prompts your pancreas to release insulin.

While many people think of these as “new” weight loss drugs, the first GLP-1 medications were actually developed to treat Type 2 diabetes. For a deeper look at the hormone behind these treatments, read what the GLP-1 hormone does in metabolism and weight management. The discovery that these drugs also led to significant weight reduction opened a new door for obesity medicine. Today, the landscape is dominated by two primary global pharmaceutical giants, but several other companies are working hard to bring new options to the pharmacy counter.

Novo Nordisk: The Market Leader

Novo Nordisk, a Danish pharmaceutical company, has been at the forefront of diabetes care for over a century. They were the first to successfully bring a GLP-1 medication to market for weight loss. Their research focuses heavily on semaglutide, a molecule that mimics the natural GLP-1 hormone but lasts much longer in the body.

Branded Medications from Novo Nordisk

Novo Nordisk is responsible for some of the most recognized names in metabolic health today. Their primary products include:

• Ozempic®: This is an injectable semaglutide medication approved by the FDA for the treatment of Type 2 diabetes. While it is often discussed in the context of weight loss, its primary indication remains blood sugar control.
• Wegovy®: This medication uses the same active ingredient, semaglutide, but is specifically FDA-approved for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition.
• Saxenda®: An older GLP-1 medication known as liraglutide. Unlike semaglutide, which is usually injected once a week, liraglutide is a daily injection.

Future Innovations

Novo Nordisk is not stopping with weekly injections. They are currently researching oral versions of semaglutide for weight loss and a new combination called CagriSema. This new candidate combines semaglutide with another hormone mimic called cagrilintide, aiming to provide even more robust metabolic support.

Eli Lilly and Company: The Major Challenger

Based in the United States, Eli Lilly has long been the primary competitor to Novo Nordisk. They have expanded the technology of GLP-1 medications by creating “dual agonists.” While semaglutide only targets the GLP-1 receptor, Eli Lilly’s latest molecule, tirzepatide, targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. If you want to see how that treatment pathway is discussed for patients, explore how to get tirzepatide for weight loss.

Branded Medications from Eli Lilly

Eli Lilly’s tirzepatide has shown significant results in clinical trials, often leading to higher percentages of weight loss compared to single-hormone mimics.

• Mounjaro®: This injectable tirzepatide is FDA-approved for the treatment of Type 2 diabetes. It works by stimulating two different satiety hormones, which helps regulate blood sugar and slow digestion.
• Zepbound®: This is the version of tirzepatide specifically FDA-approved for chronic weight management. It uses the same dual-agonist mechanism to help patients achieve significant weight reduction when combined with a reduced-calorie diet and increased physical activity.

The Pipeline at Eli Lilly

Eli Lilly is currently testing a “triple agonist” called retatrutide. This molecule targets three different receptors: GLP-1, GIP, and glucagon. The goal is to maximize the body’s energy expenditure while significantly reducing appetite. They are also working on an oral medication called orforglipron, which would eliminate the need for needles entirely.

Key Takeaway: While Novo Nordisk focuses primarily on semaglutide (GLP-1), Eli Lilly has introduced tirzepatide (GLP-1 and GIP), creating a broader range of options for metabolic treatment.

Emerging Companies in the GLP-1 Space

While Novo and Lilly currently hold the largest market share, the demand for these medications has led many other pharmaceutical companies to begin their own development programs. This competition is generally good for the healthcare system, as it can lead to more choices and better delivery methods.

Pfizer

Pfizer, one of the world’s largest pharmaceutical companies, is actively working on oral GLP-1 treatments. After some initial setbacks with twice-daily pills, they are now focused on a once-daily version of a drug called danuglipron. Their goal is to offer a convenient pill that provides similar results to the current gold-standard injections.

Amgen

Amgen is taking a slightly different approach with a candidate currently called MariTide. This drug is an “antibody-peptide conjugate.” Unlike current medications that are typically administered weekly, MariTide is being tested for monthly or even less frequent dosing. This could significantly improve the experience for patients who find weekly injections difficult to maintain.

Viking Therapeutics

Viking Therapeutics is a smaller biotech company that has gained attention for its drug candidate VK2735. Like tirzepatide, this is a dual GLP-1 and GIP agonist. Early clinical trial data suggested that their molecule might work faster or lead to fewer side effects for some patients, though more research is needed.

Roche and Zealand Pharma

Roche recently entered the space by acquiring a smaller company called Carmot Therapeutics. They are now developing several candidates, including one that could be taken as a daily pill. Zealand Pharma, another Danish company, is working on survodutide, which targets GLP-1 and glucagon receptors to help treat both obesity and liver conditions like MASH (metabolic dysfunction-associated steatohepatitis).

Comparing Current Leading Manufacturers

Company	Key Molecule	Branded Products	Mechanism
Novo Nordisk	Semaglutide	Ozempic®, Wegovy®	Single Agonist (GLP-1)
Eli Lilly	Tirzepatide	Mounjaro®, Zepbound®	Dual Agonist (GLP-1 + GIP)
AstraZeneca	Oral GLP-1	(In Development)	Single Agonist (Oral)
Amgen	MariTide	(In Development)	Dual Agonist (Monthly)

The Role of Compounded Medications

Because of the high demand and frequent supply shortages of branded medications like Wegovy® or Zepbound®, many patients have turned toward compounded versions of semaglutide and tirzepatide. It is important to understand what these are and who makes them.

Compounded medications are not made by the big pharmaceutical companies mentioned above. They are prepared by specialized, licensed compounding pharmacies. These pharmacies take the base active ingredients and create a customized version of the medication.

Note: Compounded semaglutide and compounded tirzepatide are not FDA-approved. However, we ensure that the medications prescribed through our platform are sourced from FDA-registered and inspected compounding pharmacies that follow strict quality standards.

These pharmacies play a vital role in the healthcare system, especially when name-brand drugs are on the FDA’s drug shortage list. They allow patients to continue their treatment without interruption. Our platform connects you with licensed providers who can determine if a compounded option is appropriate for your specific health needs.

Why Delivery Methods Matter

As you look at what companies make GLP-1 drugs, you will notice a race between injectable and oral formats. Most current treatments are injectables using very small, thin needles. While this is highly effective because the medicine enters the bloodstream directly, many people prefer a pill.

Injectable GLP-1s

The injectable format allows for a “slow-release” effect. This is why medications like semaglutide only need to be taken once a week. The companies making these drugs use sophisticated “pen” devices that make the process nearly painless.

Oral GLP-1s

Companies like Pfizer and Novo Nordisk are working on pills because they are easier to store and take. However, the digestive system is very good at breaking down proteins, which is what GLP-1 molecules are. Scientists have to develop special coatings or much higher doses to ensure the medicine survives the stomach and gets absorbed into the blood.

How to Access These Medications Safely

Knowing which companies make these drugs is only the first step. Because these are powerful medications that affect your hormones and metabolism, they must be used under the guidance of a healthcare professional. You cannot simply buy these medications over the counter.

The Telehealth Process

At TrimRx, we simplify the process of finding the right treatment through a telehealth-first approach. If you are ready to see whether a personalized prescription plan fits your health profile, you can complete the free assessment quiz as your next step. We believe that weight loss should be accessible, which is why we have eliminated the need for crowded waiting rooms or in-person visits.

Step 1: The Assessment Quiz You start by taking a free assessment quiz. This helps us understand your medical history, your current BMI, and your previous attempts at weight loss.

Step 2: Medical Review A licensed healthcare provider reviews your information. They look for any “contraindications”—reasons why a certain medication might not be safe for you—and determine if you are a good candidate for GLP-1 therapy.

Step 3: Personalized Treatment Plan If eligible, you receive a personalized program. This isn’t just a prescription; it’s a comprehensive approach to your health. Your medication is shipped directly from a partner pharmacy to your door.

Step 4: Ongoing Support Weight loss is a marathon, not a sprint. We provide 24/7 access to specialists who can help you manage side effects, adjust your dosage, and stay on track with your goals.

Navigating Side Effects and Support

All medications produced by these companies come with potential side effects. The most common ones are gastrointestinal, such as nausea, bloating, or changes in bowel habits. These usually happen because the medication slows down the speed at which food leaves your stomach.

To support your body during this transition, we often recommend supplemental support. For example, our GLP-1 Daily Support supplement is designed to help maintain digestive comfort and ensure you are getting the nutrients you need while your appetite is reduced.

If you are looking for an extra metabolism kick without a prescription, our Weight Loss Boost supplement is available for immediate purchase.

Bottom line: While side effects are common, they are usually manageable with the right guidance and supplemental support, and they often diminish as your body adjusts to the medication.

The Future of the GLP-1 Market

The next five to ten years will likely see a significant increase in the number of companies making GLP-1 drugs. We expect to see more “multi-agonists” that target three or even four different hunger hormones simultaneously. We also expect to see more oral options and perhaps even medications that help preserve muscle mass while you lose fat.

For readers interested in the science behind these therapies, how GLP-1 helps you lose weight is a helpful place to continue learning.

The entry of more companies may eventually help with the supply issues that have plagued the industry since 2022. As more manufacturers enter the race, the focus will shift from simply “making the drug” to “supporting the patient” through the entire process.

Our Mission at TrimRx

We are here to be your partner in this evolving landscape. We combine the latest clinical expertise with modern technology to deliver personalized, medically supervised programs that fit your life. Our mission is to help you embrace a healthier lifestyle through science, empathy, and a transparent approach to sustainable weight loss.

If you are ready to stop the cycle of failed diets and explore what modern science can do for your metabolic health, we are ready to help. Every body is different, and your weight loss program should be too.

Next Step: Take our free assessment quiz to see which personalized program is right for your health profile and goals.

FAQ

Which company makes the most popular weight loss drug?

Currently, Novo Nordisk and Eli Lilly are the two most prominent manufacturers. Novo Nordisk produces Wegovy®, while Eli Lilly produces Zepbound®. Both companies have seen massive demand for these treatments due to their effectiveness in clinical trials.

Are there any companies making GLP-1 pills instead of injections?

Yes, several companies are working on oral versions. Novo Nordisk already has an oral semaglutide approved for diabetes, and they are testing a higher-dose version for weight loss. Pfizer and Eli Lilly are also in the late stages of developing their own once-daily weight loss pills.

Do these companies also make compounded semaglutide?

No, the major pharmaceutical companies like Novo Nordisk and Eli Lilly do not manufacture compounded medications. Compounded semaglutide and tirzepatide are made by specialized, independent compounding pharmacies. These pharmacies create the medications to help fill gaps in supply or provide customized dosing.

Will more companies make these drugs in the future?

Yes, there are currently over 50 different GLP-1 related drugs in various stages of development by dozens of different companies. As more of these drugs complete clinical trials and receive regulatory approval, the number of manufacturers and treatment options will continue to grow. If you want to see whether a personalized prescription program may fit your needs, you can take the free assessment quiz.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.